This record was last updated January 8, 2026 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
KRAS is a common genetic mutation in tumors, and CRC is one of the tumors with a high KRAS mutation rate. The anti-tumor activity of KRAS G12C inhibitors combined with anti-EGFR anti-bodies have been proven in patients with advanced colorectal cancer, and one of them was approved for patients who have previously received standard treatment. However, Chinese patients still do not have access to these drugs. This study is to determine the efficacy and safety of KRAS G12C inhibitor JAB-21822 in combination with the second-line standard chemotherapy and bevacizumab in advanced colorectal cancer failed to standard therapy in Chinese population.
Protocol Amendment History
1 amendment
This ClinicalTrials.gov record has been amended once since 2025-02-18.
Status change: Recruiting → Active, Not Recruiting2026-01-06